stoxline Quote Chart Rank Option Currency Glossary
  
Eli Lilly and Company (LLY)
866.72  9.52 (1.11%)    02-19 15:59
Open: 857.175
High: 881.3268
Volume: 2,524,566
  
Pre. Close: 857.2
Low: 857.175
Market Cap: 822,791(M)
Technical analysis
2025-02-19 3:23:07 PM
Short term     
Mid term     
Targets 6-month :  1038.77 1-year :  1213.28
Resists First :  889.35 Second :  1038.77
Pivot price 847.42
Supports First :  787.79 Second :  725.01
MAs MA(5) :  862.34 MA(20) :  831.52
MA(100) :  824.2 MA(250) :  829.92
MACD MACD :  21.7 Signal :  19.9
%K %D K(14,3) :  65.7 D(3) :  71.2
RSI RSI(14): 61.7
52-week High :  972.53 Low :  711.4
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ LLY ] has closed below upper band by 32.2%. Bollinger Bands are 2.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 863.69 - 868.53 868.53 - 872.96
Low: 838.39 - 844.82 844.82 - 850.7
Close: 847.97 - 857.2 857.2 - 865.66
Company Description

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Headline News

Wed, 19 Feb 2025
ELI LILLY & Co SEC 10-K Report - TradingView

Wed, 19 Feb 2025
Eli Lilly and Company (LLY) Slid as its GLP1 Revenue Missed Expectations - Insider Monkey

Tue, 18 Feb 2025
Eli Lilly and Company (NYSE:LLY) Trading Up 1.5% - Here's What Happened - MarketBeat

Tue, 18 Feb 2025
Lilly to participate in TD Cowen's 45th Annual Health Care Conference - PR Newswire

Tue, 18 Feb 2025
The Zacks Analyst Blog Highlights Apple, Eli Lilly, Shopify and ImmuCell - Yahoo Finance

Mon, 17 Feb 2025
Why Eli Lilly and Company (LLY) Is the Best Drug Stock to Buy Now - MSN

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NYSE
Sector:
Healthcare
Industry:
Drug Manufacturers - General
Shares Out 899 (M)
Shares Float 897 (M)
Held by Insiders 0.3 (%)
Held by Institutions 83.3 (%)
Shares Short 6,770 (K)
Shares Short P.Month 6,100 (K)
Stock Financials
EPS 11.73
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 15.81
Profit Margin 23.5 %
Operating Margin 41.9 %
Return on Assets (ttm) 0 %
Return on Equity (ttm) 84 %
Qtrly Rev. Growth 44.7 %
Gross Profit (p.s.) 40.71
Sales Per Share 50.08
EBITDA (p.s.) 20.84
Qtrly Earnings Growth 101.8 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio 73.71
PEG Ratio 0
Price to Book value 54.7
Price to Sales 17.27
Price to Cash Flow 0
Stock Dividends
Dividend 1.29
Forward Dividend 0
Dividend Yield 0.1%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android